Boston Scientific Corporation is a Marlborough, Massachusetts-headquartered global medical technology leader (NYSE: BSX) with a portfolio spanning cardiovascular, MedSurg, and neuromodulation, driven by category leadership in pulsed field ablation (FARAPULSE™), structural heart (WATCHMAN™, ACURATE neo2™, SIEGEL™ TAVR), coronary intervention (SEISMIQ™ IVL), and endoscopy/urology/neuromodulation franchises. For the second quarter ended June 30, 2026, the Company generated net sales of $5.442 billion, up 7.5 percent reported (7.0 percent operational and organic) year-over-year, with GAAP net income of $907 million ($0.61 per share, up from $0.53) and adjusted EPS of $0.86 (up from $0.75, above the $0.82-0.84 guidance range). Segment performance: Cardiovascular grew 8.3 percent reported (7.8 percent organic) to $3.624 billion, led by Electrophysiology (FARAPULSE pulsed field ablation) and Structural Heart; MedSurg grew 5.9 percent reported (5.4 percent organic) to $1.818 billion, led by Endoscopy and Neuromodulation. Regional performance: U.S. +6.2%, EMEA +6.1% reported (+4.2% organic), APAC +11.2%, LACA +22.4% (+16.2% organic). The Company completed a $2 billion accelerated share repurchase (~40 million shares), invested $1.5 billion in MiRus LLC (34% equity stake + exclusive option on SIEGEL™ TAVR), and raised full-year 2026 guidance to 5.5-6.5% reported organic sales growth (from 5-7%) and adjusted EPS of $3.28-3.32. Q3 2026 guidance: 3-5% organic sales growth, adjusted EPS $0.80-0.82.
The investment thesis rests on three variables. The pulsed field ablation (FARAPULSE) adoption trajectory is the load-bearing cardiovascular variable, with the AVANT GUARD study demonstrating statistical superiority over anti-arrhythmic drugs for persistent AF, the FARAFLEX™ mapping/ablation catheter showing strong lesion durability in ELEVATE-PF, and the pivotal FARADIGM trial enrolling, creating a visible path to PFA category leadership against Medtronic's PulseSelect and Biosense Webster's VARIPULSE, and the strategic intent is to convert the clinical data package into sustained EP market share gains. The structural heart and TAVR optionality is the load-bearing structural variable, with the ACURATE neo2™ self-expanding TAVR, the WATCHMAN FLX™/FLX Pro™ LAA closure franchise, and the $1.5 billion MiRus investment (SIEGEL™ balloon-expandable TAVR, 34% stake + exclusive acquisition option) creating a dual-TAVR platform that competes with Edwards SAPIEN and Medtronic Evolut, and the strategic intent is to establish a comprehensive structural heart portfolio spanning LAA closure, self-expanding TAVR, and balloon-expandable TAVR. The MedSurg franchise resilience and Neuromodulation growth is the load-bearing diversification variable, with Endoscopy (+7.6% reported, +7.0% organic), Urology (+1.1%), and Neuromodulation (+12.7% reported, +12.2% organic) providing steady diversification, and the strategic intent is to maintain MedSurg stability while accelerating Neuromodulation through new indications and geographic expansion.